MedTrace Logo

Patients With Vulvovaginal Candidiasis

NCT03024502 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-10-19

No results posted yet for this study

Summary

The present study aims to evaluate the safety of two mucoadhesive gels containing a propolis standardized extract identified as EPP-AF, with 1 and 2% of propolis. The efficacy studies with both propolis gels will be performed in comparison with clotrimazole cream in patients presenting vulvovaginal candidiasis.

Conditions

  • Vulvovaginal Candidiasis

Interventions

DRUG

EPP-AF Gel 1%

Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days

DRUG

EPP-AF Gel 2%

Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days

DRUG

Clotrimazole

Administration intravaginal of clotrimazol, 1x/day, 7 days

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • silvana m quintana, phd · Sao Paulo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2020-01-31
Completion
2020-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03024502 on ClinicalTrials.gov